Japan· JP-4291449A2027
ベバシズマブ（遺伝子組換え）［ベバシズマブ後続１］
A medicinal product containing ベバシズマブ（遺伝子組換え）［ベバシズマブ後続１］, registered in Japan by ファイザー, on the national reimbursement list.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- ベバシズマブ（遺伝子組換え）［ベバシズマブ後続１］
- Manufacturer
- ファイザー
- Country
- Japan (JP)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
ベバシズマブ（遺伝子組換え）［ベバシズマブ後続１］ in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomAbevmy 100mg/4ml concentrate for solution for infusion vialsBiocon Biologics Ireland Ltd
- United StatesALYMSYSValorum Biologics, LLC
- CzechiaABEVMYBiosimilar Collaborations Ireland Limited, Dublin
- BelgiumAbevmy 25 mg/mlBiosimilar Collaborations Ireland
- FinlandAbevmyBiosimilar Collaborations Ireland Limited
- SwitzerlandAbevmy
- SpainABEVMY 25 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSIONBiosimilar Collaborations Ireland Limited
- CanadaABEVMYBIOSIMILAR COLLABORATIONS IRELAND LIMITED
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Oyavas
- Iceland · Abevmy, Alymsys
- Liechtenstein · Abevmy, Alymsys
- Norway · Abevmy, Alymsys
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/38a54db5-d653-4b3c-82f0-91365ecb4d35 GET /v1/drugs/38a54db5-d653-4b3c-82f0-91365ecb4d35?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "４００ｍｇ１６ｍＬ１瓶",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "4291449A2027",
"category": "注射薬",
"price_yen": 22130,
"generic_name": "ベバシズマブ（遺伝子組換え）［ベバシズマブ後続１］",
"product_name_jp": null,
"therapeutic_class": "4291",
"transitional_expiry": null
}See everything about ベバシズマブ（遺伝子組換え）［ベバシズマブ後続１］.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.